GlassScriptPhysician profile
Paul Stafford
NPI 1396735759
$8,207.72
in general payments reported to CMS, 2019-2025
34 companies · $2,095 in 2025
The $2,095 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,828 · 2020: $908 · 2021: $653 · 2022: $978 · 2023: $917 · 2024: $829 · 2025: $2,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,867 · Travel and Lodging: $813 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,867.44 |
| Travel and Lodging | $813.42 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,529.67 | 2019-2025 | Ingevity+, Accolade Sr, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $647.76 | 2021-2025 | Corevalve Evolut R, Selectsecure, Symplicity G3 |
| Pfizer INC. | $582.50 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $292.13 | 2020-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $288.94 | 2019-2025 | Eliquis, Camzyos |
| Actelion Pharmaceuticals US, INC. | $243.53 | 2019-2025 | Opsumit, Uptravi |
| Abiomed | $227.20 | 2019-2023 | Impella |
| Sanofi-Aventis U.S. LLC | $219.29 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $190.19 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $131.93 | 2022-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.90 | 2019-2022 | |
| Amgen INC. | $102.07 | 2019-2024 | Repatha |
| Atricure, INC. | $66.53 | 2019 | |
| Itamar Medical INC | $58.55 | 2022-2023 | Watchpatone |
| Medtronic Vascular, INC. | $58.09 | 2019-2020 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $46.73 | 2023-2024 | Barostim Neo System |
| Kestra Medical Technology Services, INC. | $44.02 | 2024-2025 | Assure Wcd |
| Recor Medical INC | $42.03 | 2024-2025 | Paradise Renal Denervation System, Paradise Ultrasound Renal Denervation System |
| Astellas Pharma US INC | $41.45 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $35.60 | 2024 | Arcalyst |
| Philips North America LLC | $31.72 | 2023-2025 | Ecc Solutions |
| Lundbeck LLC | $24.27 | 2019 | |
| Abbott Laboratories | $24.08 | 2025 | Diamondback Coronary |
| Braemar Manufacturing, LLC | $18.45 | 2019 | |
| Daiichi Sankyo INC. | $18.30 | 2023 | Injectafer |
| Akcea Therapeutics, INC. | $18.23 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.29 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $16.76 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.20 | 2025 | Voquezna |
| Endologix LLC | $16.13 | 2022 | |
| Arbor Pharmaceuticals, INC. | $14.39 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $14.06 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $13.35 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $11.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Stafford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.